<DOC>
	<DOCNO>NCT01209325</DOCNO>
	<brief_summary>RATIONALE : Vaccines make gene-modified virus may help body build effective immune response prevent viral infection . PURPOSE : This phase II trial study well vaccine therapy work prevent human papillomavirus ( HPV ) infection young HIV-positive male patient sex male .</brief_summary>
	<brief_title>Vaccine Therapy Preventing Human Papillomavirus Infection Young HIV-Positive Male Patients Who Have Sex With Males</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine protective effect HPV-6 , -11 , -16 , -18 vaccine prevent penile/scrotal condyloma HPV-6 , -11 , -16 , -18- associate perianal/anal disease HIV-positive male sex male ( MSM ) age 13-26 year compare incidence lesion among naïve relevant HPV type ( ) baseline naïve baseline . - To determine protective effect HPV-6 , -11 , -16 , -18 vaccine prevent persistent anogenital infection HPV-6 , -11 , -16 , 18 HIV-positive MSM age 13-26 year compare incidence persistent infection among naïve relevant HPV type ( ) baseline naïve baseline . - To determine protective effect HPV-6 , -11 , -16 , -18 vaccine prevent anogenital lesion associate HPV 6 , -11 , -16 , -18 persistent infection type , HIV-positive MSM age 13-26 year compare incidence lesion persistent infection among naïve relevant type baseline incident lesion infection among MSM naïve HPV type participate Merck 020 protocol receive placebo part protocol . Secondary - To define safety HPV-6 , -11 , -16 , -18 vaccine HIV-positive MSM age 13-26 year . - To evaluate level persistence HPV 6 , 11 , 16 18 Ab titer vaccination series among subject seropositive seronegative baseline . - To examine whether protective effect antibody titer vary function follow time initial vaccination : subject age , HAART treatment status , HIV viral load , CD4 + T-cell count , nadir CD4 level . Tertiary - To quantify anogenital HPV DNA viral load prior receipt quadrivalent HPV vaccine . - To identify quantify HPV type oral cavity HIV-positive MSM prior receipt quadrivalent HPV vaccine . - To identify HPV strain variant among HIV-positive participant prior receipt quadrivalent HPV vaccine . - Assess prevalence incidence urinary gonorrhea Chlamydia trachomatis infection baseline relationship prevalent incident anogenital HPV infection anal condyloma AIN . - To characterize young men 's risk perception , sexual behavior , STI diagnosis HPV vaccination . OUTLINE : This multicenter study . Patients receive quadrivalent human papillomavirus ( type 6 , 11 , 16 , 18 ) recombinant vaccine intramuscularly day 1 week 8 24 . Blood tissue sample may collect periodically laboratory study . After completion study treatment , patient follow 2 year .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anus Neoplasms</mesh_term>
	<mesh_term>Papillomavirus Infections</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Penile Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Men history least one male sexual partner `` Men '' define document `` male '' birth ( include maletofemale transgendered person ) HIV1 infection document federally approve , license HIV test perform conjunction screening ( ELISA , western blot , approve test ) Alternatively , documentation may include record another physician document patient HIV base prior ELISA western blot , approve diagnostic test Meets one follow set criterion : Patients receive antiretroviral therapy : Receipt antiretroviral therapy least 3 month prior entry No change antiretroviral therapy within 30 day prior entry Patients receive antiretroviral therapy : CD4cell count ≥ 350 cells/mm³ within 90 day prior study entry No plan start antiretroviral therapy prior Week 28 Normal anal cytological result , LSIL/condyloma , ASCUS result within 90 day prior entry , HGAIN biopsy No current history anal perianal carcinoma No anal cytological result HSIL , atypical squamous cell suggestive HSIL ( ASCH ) , suggestive invasive carcinoma screening ; history result No presence penile scrotal condyloma , LGAIN ( condyloma AIN 1 ) , HGAIN ( e.g. , AIN 2 3 , perianal intraepithelial neoplasia grade 2 3 ) , invasive carcinoma preentry biopsy No history HGAIN PATIENT CHARACTERISTICS : Karnofsky performance score ≥ 70 within 45 day prior entry Absolute neutrophil count ( ANC ) &gt; 750 cells/mm^3 Hemoglobin ≥ 9.0 g/dL Platelet count ≥ 100,000/mm^3 AST ( SGOT ) , ALT ( SGPT ) ≤ 3 time upper limit normal ( ULN ) Total conjugate ( direct ) bilirubin ≤ 2.5 time ULN within 45 day study entry , exception isolate hyperbilirubinemia consider due atazanavir Calculated creatinine clearance ≥ 60 mL/min No hemophilia No active drug alcohol use dependence , opinion site Investigator , would interfere adherence study requirement No serious illness require systemic treatment and/or hospitalization within 45 day prior entry No serious medical psychiatric illness , opinion site Investigator , interfere ability subject give inform consent adhere protocol No allergy yeast component Gardasil PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior splenectomy No prior receipt Gardasil HPV vaccine No use systemic antineoplastic immunomodulatory treatment , systemic corticosteroid great 14 day , investigational vaccine , interleukin , interferon , growth factor , IVIG within 45 day prior study entry No expect use systemic antineoplastic immunomodulatory treatment , systemic corticosteroid use great 14 day , investigational vaccine , interleukin , interferon , growth factor , IVIG study followup No patient hepatitis C expect initiate treatment hepatitis C ( e.g. , interferon ) trial Not currently receive anticoagulation therapy acetylsalicylic acid</criteria>
	<gender>Male</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>26 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>human papilloma virus infection</keyword>
	<keyword>anal cancer</keyword>
	<keyword>penile cancer</keyword>
	<keyword>HIV infection</keyword>
</DOC>